Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. And Korea Step Up Fight Against Tuberculosis, Launch TB Research Center

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a bid to wipe out perceptions that South Korea remains a "safe heaven" for tuberculosis, the country is strengthening cooperation with the U.S. in a joint attack on the potentially fatal disease
Advertisement

Related Content

South Korea Gearing Up To Fight Tuberculosis
Korea And U.S. Health Ministers Agree To Enhance Cooperation In Anticipation Of Increased Pharma, Device Trade
Korea And U.S. Health Ministers Agree To Enhance Cooperation In Anticipation Of Increased Pharma, Device Trade
American Chamber of Commerce in Korea, PhRMA Join Forces To Help Boost Korean Healthcare Drive
American Chamber of Commerce in Korea, PhRMA Join Forces To Help Boost Korean Healthcare Drive
Korea, Singapore Institutes Sign MOU On Nanotechnology Applications
Korea, Singapore Institutes Sign MOU On Nanotechnology Applications
Advertisement
UsernamePublicRestriction

Register

SC071120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel